The goal of the proposed research is to contribute to the elucidation of the molecular mechanism of Alzheimer's disease with a focus on the deficits observed in synaptic transmission, synaptic plasticity and memory and learning in a mouse model of Alzheimer's disease. The mouse model that will be used in the experiments is a mouse engineered to over expressing the human APP protein carrying mutations which are known to cause Alzheimer's disease in humans. We have demonstrated that these mice exhibit deficits in synaptic transmission, synaptic plasticity, and spatial learning. We will also examine the role of neurogenesis and exercise in Alzheimer's disease.
Aim 1 of this proposal is to examine the role of nicotinic receptors in Alzheimer's disease. Behavioral studies have linked the cholinergic system to learning and memory, which is intriguing given the observation that Alzheimer's patients have a deficiency in memory function and cortical nicotinic receptors. The first class of drugs approved for the treatment of Alzheimer's disease, which still today constitutes the best available treatment, are the cholinesterase inhibitors (Tacrine, Donepezil, Rivastigmine, Galantamine), which boost cholinergic function.
Aim 1 of this proposal will be to test the hypothesis that binding of the beta-amyloid fragment (1-42) to the nicotinic receptor alpha 7 leads to the pathology seen in Alzheimer's disease. These experiments may either support or refute the idea that the cholinergic receptor system plays an important role in Alzheimer's disease. Either outcome will provide important information for developing strategies to prevent or reverse Alzheimer's disease.
Aim 2 of this proposal is to test the role of the APP C-terminal caspase cleavage site and its proteolytic products in Alzheimer's disease. We have shown that mice over expressing the mutant human APP protein that causes human Alzheimer's disease exhibit deficits in synaptic transmission, synaptic plasticity and spatial learning. On the other hand, mice expressing the same mutant APP protein but with a deletion of a caspase cleavage site near the APP protein c-terminal are protected from the deficits. These observations predict that APP cterminal proteolytic fragments are causing synaptic damage and this hypothesis will be tested directly.

Public Health Relevance

Our genetic studies will test ideas about the involvement of neurotransmitter receptors, exercise, and neurogenesis in the mechanism of Alzheimer's disease. We will also test the hypothesis that proteolytic cleavage of the APP protein is an essential step in the development of Alzheimer's disease. The results and insights from these studies should make it possible to develop new targets for drug therapy to treat Alzheimers's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG010435-17A2
Application #
7786586
Study Section
Special Emphasis Panel (ZAG1-ZIJ-6 (O4))
Project Start
Project End
Budget Start
2010-04-15
Budget End
2010-11-30
Support Year
17
Fiscal Year
2010
Total Cost
$282,100
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Chen, Zhijiang; Donnelly, Christopher R; Dominguez, Bertha et al. (2017) p75 Is Required for the Establishment of Postnatal Sensory Neuron Diversity by Potentiating Ret Signaling. Cell Rep 21:707-720
Hirai, Maretoshi; Arita, Yoh; McGlade, C Jane et al. (2017) Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J Clin Invest 127:569-582
Kratter, Ian H; Zahed, Hengameh; Lau, Alice et al. (2016) Serine 421 regulates mutant huntingtin toxicity and clearance in mice. J Clin Invest 126:3585-97
Spencer, Brian; Desplats, Paula A; Overk, Cassia R et al. (2016) Reducing Endogenous ?-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci 36:7971-84
Spencer, Brian; Potkar, Rewati; Metcalf, Jeff et al. (2016) Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. J Biol Chem 291:1905-20
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34
Wang, Ling; Conner, James M; Nagahara, Alan H et al. (2016) Rehabilitation drives enhancement of neuronal structure in functionally relevant neuronal subsets. Proc Natl Acad Sci U S A 113:2750-5
van den Hurk, Mark; Kenis, Gunter; Bardy, Cedric et al. (2016) Transcriptional and epigenetic mechanisms of cellular reprogramming to induced pluripotency. Epigenomics 8:1131-49
Xu, Jiqing; de Winter, Fred; Farrokhi, Catherine et al. (2016) Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model. Sci Rep 6:31692
Biane, Jeremy S; Takashima, Yoshio; Scanziani, Massimo et al. (2016) Thalamocortical Projections onto Behaviorally Relevant Neurons Exhibit Plasticity during Adult Motor Learning. Neuron 89:1173-1179

Showing the most recent 10 out of 181 publications